Mahmoud A. Pouladi
« start a new directory search
FACULTY & STAFF DIRECTORY
Profile photo
Mahmoud A. Pouladi
MSc, PhD
Research Scientist
Group Hayden Lab
Email
Direct line +1 (604) 875-3808
Fax +1 (604) 875-3819

ADDITIONAL CONTACT INFORMATION

Location Room 3002
 
Centre for Molecular Medicine and Therapeutics
950 West 28th Avenue
Vancouver, BC
V5Z 4H4 Canada

EDUCATION

BSc, McMaster University (2001)
MSc, McMaster University (2004)
PhD, University of British Columbia (2010)

PRESENTATIONS

26th Annual Huntington’s Disease Society of America Convention, 2011, Minneapolis, USA:
Synaptic dysfunction as a target for therapy for Huntington disease

4th Annual Huntington’s Disease Therapeutics Conference: A Forum for Drug Discovery & Development, 2009, Cannes, France:
Pouladi MA, Graham RK, Bertram L, Dar Santos R., Xie Y, Schwab C, Zapala M, Metzler M, Leavitt BR, and Hayden MR. A controlled trial of memantine, an NMDA receptor antagonist, in combination with the propargylamine rasagiline in a mouse model of Huntington disease.

Pacific Northwest Chapter Meeting of the Society for Neuroscience, 2008, Vancouver, BC:
Pouladi MA, Graham RK, Karasinska J, Xie Y, Dar Santos R, Petersén Å, and Hayden MR. Prevention of cleavage of mutant huntingtin by caspase-6 alleviates the depressive behaviour in the YAC128 mouse model of Huntington disease.

The 1st Reisensburg Workshop—The Metabolic System as a Therapeutic Target in HD, 2008, Gunzburg, Germany:
Pouladi MA, Xie Y, Leavitt B, and Hayden MR. Role of Huntingtin in Body Weight Regulation.

Publications

Reviews and Invited Reviews

1   Review   Pouladi MA. Fragile X Syndrome therapy: to respond or not to respond may be a matter of methylation. Clinical Genetics (2011) PMID 21388370
2   Review   Pouladi MA. Taking a SUMO off a TRP for bad conduct. Clinical Genetics 77(4):328-30. (2010) PMID 20095982
3   Review   Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: variations on a theme. Dis Model Mech 2(3-4):123-9. (2009) PMID 19259385
4   Review   Pouladi MA. Jewels in the rough - the study of non-coding genomic sequences as a conduit to understanding human disease Clinical Genetics 69(2):118-119. (2006)
5   Review   Pouladi MA. Juvenile myoclonic epilepsy, calcium and the EF hand of death Clinical Genetics 67(4):301-302. (2005)
6   Review   Pouladi MA. A link between ALOX5AP and myocardial infarction and stroke Clinical Genetics 66(1):18-20. (2004)

Journal Articles

1   Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. (2012) PMID 22328089
2   Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, Ehrnhoefer DE, Vaid K, Miller FD, Deshmukh M, Howland D, Hayden MR. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. (2012) PMID 22262731
3   Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, Perkins G, Bossy-Wetzel E. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 17(3):377-82. (2011) PMID 21336284
4   Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR. Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 Activation In Vivo. J. Neurosci. 30(45):15019-15029. (2010) PMID 21068307
5   Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of huntington disease. Neurobiol. Dis. (2010) PMID 20875859
6   Valenza M, Leoni V, Karasinska JM, Petricca L, Fan J, Carroll J, Pouladi MA, Fossale E, Nguyen HP, Riess O, Macdonald M, Wellington C, Didonato S, Hayden M, Cattaneo E. Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. J. Neurosci. 30(32):10844-10850. (2010) PMID 20702713
7   Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Neuron 65(2):178-190. (2010) PMID 20152125
8   Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet. (2010) PMID 20097678
9   Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. (2010) PMID 20089533
10   Okamoto SI*, Pouladi MA*, Talantova M*, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR**, Lipton SA** (*co-first authors; **co-senior authors). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15(12):1407-13. (2009) PMID 19915593
11   Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 29(7):2193-204. (2009) PMID 19228972
12   Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 132(Pt 4):919-32. (2009) PMID 19224899
13   MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(3):341-7. (2009) PMID 19095997
14   Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Möller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 205(8):1869-77. (2008) PMID 18625748
15   Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 16(15):1845-61. (2007) PMID 17519223
16   Robbins CS*, Pouladi MA*, Fattouh R, Dawe DE, Vujicic N, Richards CD, Jordana M, Inman MD, Stampfli MR (*equal contribution). Mainstream cigarette smoke exposure attenuates airway immune inflammatory responses to surrogate and common environmental allergens in mice, despite evidence of increased systemic sensitization. J. Immunol. 175(5):2834-42. (2005) PMID 16116169
17   Fattouh R, Pouladi MA, Alvarez D, Johnson JR, Walker TD, Goncharova S, Inman MD, Jordana M. House dust mite facilitates ovalbumin-specific allergic sensitization and airway inflammation. Am. J. Respir. Crit. Care Med. 172(3):314-21. (2005) PMID 15879422
18   Drannik AG, Pouladi MA, Robbins CS, Goncharova SI, Kianpour S, Stämpfli MR. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 170(11):1164-71. (2004) PMID 15317669
19   Swirski FK, Gajewska BU, Robbins CS, D'Sa A, Johnson JR, Pouladi MA, Inman MD, Stämpfli MR. Concomitant airway expression of granulocyte-macrophage colony-stimulating factor and decorin, a natural inhibitor of transforming growth factor-beta, breaks established inhalation tolerance. Eur. J. Immunol. 34(9):2375-86. (2004) PMID 15307170
20   Robbins CS, Dawe DE, Goncharova SI, Pouladi MA, Drannik AG, Swirski FK, Cox G, Stämpfli MR. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral immune responsiveness. Am. J. Respir. Cell Mol. Biol. 30(2):202-11. (2004) PMID 12920055
21   Pouladi MA, Robbins CS, Swirski FK, Cundall M, McKenzie AN, Jordana M, Shapiro SD, Stämpfli MR. Interleukin-13-dependent expression of matrix metalloproteinase-12 is required for the development of airway eosinophilia in mice. Am. J. Respir. Cell Mol. Biol. 30(1):84-90. (2004) PMID 12842850
22   Coppolino MG, Dierckman R, Loijens J, Collins RF, Pouladi M, Jongstra-Bilen J, Schreiber AD, Trimble WS, Anderson R, Grinstein S. Inhibition of phosphatidylinositol-4-phosphate 5-kinase Ialpha impairs localized actin remodeling and suppresses phagocytosis. J. Biol. Chem. 277(46):43849-57. (2002) PMID 12223494

Invited Submissions, Books, Chapters, Letters, and Editorials

1   Chapter   Pouladi MA, Hayden MR. Introduction to Huntington's Disease Huntington's Dementia (2008)
2   Chapter   Hayden MR, Pouladi MA, Kremer B . Basal Ganglia Disorders Emery & Rimoin's Principles and Practice of Medical Genetics, fifth ed (2006)
3   Chapter   Pouladi MA, Bezprozvanny I, Raymond LA, Hayden MR. Molecular Pathogenesis of Huntington's Disease: The Role of Excitotoxicity Genetic Instabilities and Neurological Diseases, 2nd ed (2006)